Key Highlights
- $500 billion in revenue is at risk from patent expiries, and dealmaking has returned to pre-pandemic highs as pharma races to secure new growth ahead of the cliff.
- China’s share of global biopharma activity continues to grow, now sitting at roughly 30%, though speakers were clear that blocking these deals isn’t the fix Western biotech needs.
- AI is increasingly treated as deal currency, but the platforms getting the most attention pair computational power with real lab validation, and data quality still beats model sophistication.
The infographic also rounds up the buzzwords of the year (“Lab-in-the-loop” and “boundary defiant” both made the cut) and some of the sharpest quotes from the panel sessions, including a few on what biotech still gets wrong about rare disease and why GLP-1s only solved the easy part of metabolic disease.
View the infographic below, or visit our BIO International 2026 content hub for more.
